Opendata, web and dolomites

Capsulight

The first ingestible capsule for eradicating Helicobacter pylori infection through photodynamic therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Capsulight project word cloud

Explore the words cloud of the Capsulight project. It provides you a very rough idea of what is the project "Capsulight" about.

biopsies    once    specialized    economic    reaching    patented    secondary    cycles    hospitalization    medicine    capsules    savings    97    healthcare    ce    superiore    world    cured    biopsy    gastric    centers    pylori    device    anna    tests    national    validation    mass    rate    robotics    30    population    therapies    probiomedica    capsule    unfortunately    bacterium    undergo    off    power    eradicate    optimize    therapy    cancers    capsulight    possibility    advantages    light    pump    carcinogen    countries    clinical    antibiotic    photobiology    safety    resistance    despite    photodynamic    usually    diagnostic    spin    inhibitor    vitro    first    treatment    mark    stomach    90    killing    presented    helicobacter    efficacy    ingestible    50    preliminary    market    reducing    drug    posology    assumption    pharmacological    mix    infection    agent    70    drugs    infected    diagnosed    intragastric    attributable    proton    endoscopic    scuola    sant    showed    gastroenterology    eradicated    miniaturization    florence    unparalleled    microbiology    university   

Project "Capsulight" data sheet

The following table provides information about the project.

Coordinator
PROBIOMEDICA SRL 

Organization address
address: VIA DI BELLOSGUARDO 2 ROSSO
city: FIRENZE
postcode: 50124
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website https://www.probiomedica.it
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PROBIOMEDICA SRL IT (FIRENZE) coordinator 50˙000.00

Map

 Project objective

Helicobacter pylori (H. pylori) is a bacterium of the stomach which affects on average 50% of the world population, reaching up to 70% in some European Countries. Once it is diagnosed, it has to be eradicated, since it is a carcinogen agent and around 90% of all gastric cancers can be attributable to its infection. The only available treatment is a pharmacological therapy based on the assumption of proton-pump inhibitor and a mix of 2-3 antibiotic drugs. Unfortunately, due to increasing antibiotic resistance, up to 30% of the affected population cannot be cured, despite several cycles of antibiotic therapy and usually endoscopic biopsy to determine antibiotic-resistance. Probiomedica is a spin-off of the University of Florence and Scuola Superiore Sant’Anna specialized in photobiology and robotics applied to medicine, which has developed and patented CapsuLight, the first ingestible capsule able to eradicate H. Pylori infection through intragastric photodynamic therapy, that is through the power of light. The device is based on the established technology and safety of endoscopic capsules for diagnostic use, and our preliminary in vitro tests showed 97% efficacy in killing the bacterium. The advantages for infected population are unparalleled: the possibility to eradicate the bacterium for those who cannot be cured due to antibiotic resistance (our first target market); the higher efficacy rate, no side effects due to antibiotic cycles, and easy posology for all the infected population (secondary market). CapsuLight will also provide high economic savings to National Healthcare Systems, by reducing drug therapies cycles and endoscopic biopsies and related costs for hospitalization. Probiomedica has already presented the product to several gastroenterology and microbiology centers and will optimize the capsule design for further miniaturization and mass production, and to undergo the necessary clinical validation for getting the CE mark during the Phase 2 project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAPSULIGHT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CAPSULIGHT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

Presque (2019)

Smart Nursing Bra

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More